Shi, Jing <br/><br/>
Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.  [electronic resource] 

 -  Journal for immunotherapy of cancer  09 2019 
 - 246 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2051-1426 
<br/><br/><label>Standard No.: </label>10.1186/s40425-019-0725-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis<br/>CD8-Positive T-Lymphocytes--drug effects<br/>Cell Proliferation<br/>Drug Therapy, Combination<br/>Flavones--pharmacology<br/>Humans<br/>Immunotherapy<br/>Indoleamine-Pyrrole 2,3,-Dioxygenase--antagonists & inhibitors<br/>Kynurenine--metabolism<br/>Lymphocyte Activation--immunology<br/>Melanoma--drug therapy<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Inbred C57BL<br/>Mice, Transgenic<br/>Receptors, Aryl Hydrocarbon--antagonists & inhibitors<br/>Triazoles--pharmacology<br/>Tryptophan--pharmacology<br/>Tumor Cells, Cultured<br/>Tumor Microenvironment--drug effects